Home › Cases › Sickle Cell — Acute Chest Syndrome
Sickle Cell Crisis
Sickle Cell — Acute Chest Syndrome
6 questions
Question 1 · ACS recognition
Correct answer: Acute chest syndrome (ACS) — new pulmonary infiltrate + one of: fever, cough, respiratory symptoms, hypoxia. Commonest cause of death in SCD adults
Why
Acute Chest Syndrome (ACS): new pulmonary infiltrate on CXR + ≥1 of: fever >38.5°C, SpO2 fall >3% or <95%, tachypnoea/dyspnoea/chest pain. Can develop from: fat embolism (from infarcted marrow), infection (atypicals, pneumococcus), sickling in pulmonary vasculature. Commonest cause of sickle cell death in adults. Rapid deterioration possible.
Key point
ACS: new CXR infiltrate + fever/hypoxia/chest symptoms in SCD. Commonest adult SCD death. Rapid progression — escalate early.
Question 2 · ACS treatment
Correct answer: Exchange transfusion (urgent): reduces HbS to <30%. High-flow O2. Antibiotics (ceftriaxone + azithromycin). Incentive spirometry. Low threshold for ICU/HDU
Why
ACS management:
- Simple transfusion if Hb <60 g/L
- Exchange transfusion if rapid deterioration, Hb >60 (simple transfusion would raise viscosity too much) — target HbS <30%
- Antibiotics: ceftriaxone (Pneumococcus, H. influenzae) + azithromycin (Mycoplasma, Chlamydia — common in ACS)
- High-flow O2
- Incentive spirometry + good analgesia (prevent splinting)
- Bronchodilators if wheeze
Key point
ACS: exchange transfusion (HbS <30%) + antibiotics (ceftriaxone + azithromycin) + O2 + incentive spirometry. ICU if deteriorating.
Question 3 · Incentive spirometry
Correct answer: Sickle cell + pain → splinting (shallow breathing) → atelectasis → hypoxia → HbS polymerisation → ACS. Incentive spirometry prevents atelectasis and ACS development
Why
Incentive spirometry in SCD: bone/chest pain causes splinting (patients breathe shallowly to avoid pain) → atelectasis → hypoxia → HbS polymerisation → ACS cycle. Incentive spirometry: trains deep breathing, re-expands collapsed lung segments. Evidence: routine use reduces ACS incidence. Also: adequate analgesia essential (prevents splinting).
Key point
Incentive spirometry: prevents splinting → atelectasis → hypoxia → ACS cycle. Routine in all sickle cell admissions with chest/abdominal pain.
Question 4 · Hydroxyurea (hydroxycarbamide)
Correct answer: Hydroxycarbamide (hydroxyurea): increases HbF production → dilutes HbS → reduces sickling. Reduces ACS, pain crises, hospitalisation, and mortality
Why
Hydroxycarbamide (hydroxyurea): increases fetal haemoglobin (HbF) — HbF does not polymerise with HbS → reduces sickling. MSH trial (1995): 44% reduction in pain crises, 50% reduction in ACS. Also reduces hospitalisations and mortality. All SCD patients with ≥3 crises/year or any ACS should be offered it. Side effects: myelosuppression (monitor FBC), teratogenic.
Key point
Hydroxycarbamide: increases HbF → reduces sickling. 44% pain crisis reduction, 50% ACS reduction (MSH trial). Indicated for ≥3 crises/year or ACS.
Question 5 · Infection prophylaxis
Correct answer: Functional asplenia: sickled cells block splenic sinusoids → progressive splenic infarction → autosplenectomy. Loss of splenic phagocytic function → susceptibility to encapsulated bacteria (pneumococcus, H. influenzae, meningococcus)
Why
SCD functional asplenia: repeated splenic sickling → infarction → functional loss (autosplenectomy) by age 5-6. Encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) clearance depends on spleen. Prophylaxis: penicillin V 500mg BD lifelong (or amoxicillin). Vaccines: PCV13 + PPV23, MenACWY, MenB, Hib. Annual flu vaccine.
Key point
SCD: functional asplenia by ~age 5. Penicillin prophylaxis lifelong. Vaccines: pneumococcal (PCV+PPV), MenACWY, MenB, Hib, flu.
Question 6 · Bone marrow transplant
Correct answer: Allogenic haematopoietic stem cell transplant (HSCT) from HLA-matched sibling: only established cure. Best outcomes in children with matched sibling donor. Gene therapy: emerging (betibeglogene — FDA approved 2023)
Why
SCD cure: allogeneic HSCT from HLA-matched sibling donor: 90%+ cure rate in children. Disease-free survival excellent if matched sibling. Risks: GVHD, transplant-related mortality (5%). Limited by donor availability. Gene therapy (betibeglogene spartacus): FDA approved 2023 — adds functional β-globin gene, highly effective. CRISPR gene editing (exa-cel) also approved — reactivates HbF.
Key point
SCD cure: HSCT from HLA-matched sibling (90% success, children). Gene therapy emerging (betibeglogene, exa-cel). Limited by donor availability.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.